Volume of Interest Delineation Techniques for F-FDG PET-CT Scans During Neoadjuvant Extremity Soft Tissue Sarcoma Treatment in Adults: a Feasibility Study

Overview

Journal EJNMMI Res

Date 2018 Jun 9

PMID 29881881

Citations 2

Authors

Marc G Stevenson

Lukas B Been

Harald J Hoekstra

Albert J H Suurmeijer

Ronald Boellaard

Adrienne H Brouwers

Affiliations

Soon will be listed here.

Abstract

Background: This study explores various volume of interest (VOI) delineation techniques for fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography (F-FDG PET-CT) scans during neoadjuvant extremity soft tissue sarcoma (ESTS) treatment.

Results: During neoadjuvant treatment, hyperthermic isolated limb perfusion (HILP) and preoperative external beam radiotherapy (EBRT), 11 patients underwent three F-FDG PET-CT scans. The first scan was made prior to the HILP, the second after the HILP but prior to the start of the EBRT, and the third prior to surgical resection. An automatically drawn VOI, a manually drawn VOI, and two gradient-based semi-automatically drawn VOIs (VOI and VOI) were obtained. Maximum standardized uptake value (SUV), SUV, SUV, metabolically active tumor volume (MATV), and total lesion glycolysis (TLG) were calculated from each VOI. The correlation and level of agreement between VOI delineation techniques was explored. Lastly, the changes in metabolic tumor activity were related to the histopathologic response. The strongest correlation and an acceptable level of agreement was found between the VOI and the VOI delineation techniques. A decline (VOI) in SUVmax, SUVpeak, SUVmean, TLG, and MATV (all p < 0.05) was found between the three scans. A > 75% decline in TLG between scan 1 and scan 3 possibly identifies histopathologic response.

Conclusions: The VOI delineation technique was identified as most reliable considering reproducibility when compared with the other VOI delineation techniques during the multimodality neoadjuvant treatment of locally advanced ESTS. A significant decline in metabolic tumor activity during the treatment was found. TLG deserves further exploration as predictor for histopathologic response after multimodality ESTS treatment.

Citing Articles

Current uses and understanding of PET imaging in cardiac sarcoidosis.

Madiraju A, Bhattaru A, Pham T, Pundyavana A, Rojulpote K, Raynor W Am J Nucl Med Mol Imaging. 2024; 14(3):161-174.

PMID: 39027647 PMC: 11253081. DOI: 10.62347/NANX3492.

PET segmentation of bulky tumors: Strategies and workflows to improve inter-observer variability.

Pfaehler E, Burggraaff C, Kramer G, Zijlstra J, Hoekstra O, Jalving M PLoS One. 2020; 15(3):e0230901.

PMID: 32226030 PMC: 7105134. DOI: 10.1371/journal.pone.0230901.

References

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev. 2000; (4):CD001419. DOI: 10.1002/14651858.CD001419. View

Chen H, Chiu N, Su W, Guo H, Lee B . Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012; 264(2):559-66. DOI: 10.1148/radiol.12111148. View

Le Cesne A, Ouali M, Leahy M, Santoro A, Hoekstra H, Hohenberger P . Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014; 25(12):2425-2432. DOI: 10.1093/annonc/mdu460. View

van Helden E, Hoekstra O, Boellaard R, Roth C, Mulder E, Verheul H . Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PLoS One. 2016; 11(5):e0155178. PMC: 4873260. DOI: 10.1371/journal.pone.0155178. View

Boellaard R, Krak N, Hoekstra O, Lammertsma A . Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004; 45(9):1519-27. View

Saponara M, Stacchiotti S, Casali P, Gronchi A . (Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. Eur J Cancer. 2016; 70:1-11. DOI: 10.1016/j.ejca.2016.09.030. View

van Ginkel R, Hoekstra H, Pruim J, Nieweg O, Molenaar W, Paans A . FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med. 1996; 37(6):984-90. View

Hoven-Gondrie M, Bastiaannet E, van Ginkel R, Suurmeijer A, Hoekstra H . TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome. J Surg Oncol. 2011; 103(7):648-55. DOI: 10.1002/jso.21885. View

10.

Lodge M, Chaudhry M, Wahl R . Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012; 53(7):1041-7. PMC: 3417317. DOI: 10.2967/jnumed.111.101733. View

11.

Kramer G, Frings V, Hoetjes N, Hoekstra O, Smit E, de Langen A . Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2016; 57(9):1343-9. DOI: 10.2967/jnumed.115.170225. View

12.

Hoven-Gondrie M, Bastiaannet E, van Ginkel R, Pras E, Suurmeijer A, Hoekstra H . [Limb perfusion in soft tissue sarcomas: twenty years of experience]. Ned Tijdschr Geneeskd. 2013; 157(30):A6148. View

13.

Morrison B . Soft tissue sarcomas of the extremities. Proc (Bayl Univ Med Cent). 2005; 16(3):285-90. PMC: 1200782. DOI: 10.1080/08998280.2003.11927915. View

14.

Stevenson M, Seinen J, Pras E, Brouwers A, van Ginkel R, van Leeuwen B . Hyperthermic isolated limb perfusion, preoperative radiotherapy, and surgery (PRS) a new limb saving treatment strategy for locally advanced sarcomas. J Surg Oncol. 2018; 117(7):1447-1454. DOI: 10.1002/jso.25008. View

15.

Frings V, van Velden F, Velasquez L, Hayes W, van de Ven P, Hoekstra O . Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. Radiology. 2014; 273(2):539-48. DOI: 10.1148/radiol.14132807. View

16.

Bhangu A, Broom L, Nepogodiev D, Gourevitch D, Desai A . Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review. Eur J Surg Oncol. 2013; 39(4):311-9. DOI: 10.1016/j.ejso.2012.12.018. View

17.

Casey D, Wexler L, Fox J, Dharmarajan K, Schoder H, Price A . Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2014; 90(5):1136-42. DOI: 10.1016/j.ijrobp.2014.08.005. View

18.

Wardelmann E, Haas R, Bovee J, Terrier P, Lazar A, Messiou C . Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur J Cancer. 2015; 53:84-95. DOI: 10.1016/j.ejca.2015.09.021. View

19.

Eggermont A, Schraffordt Koops H, Lienard D, Kroon B, van Geel A, Hoekstra H . Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996; 14(10):2653-65. DOI: 10.1200/JCO.1996.14.10.2653. View

20.

Eggermont A, Schraffordt Koops H, Klausner J, Kroon B, Schlag P, Lienard D . Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996; 224(6):756-64; discussion 764-5. PMC: 1235474. DOI: 10.1097/00000658-199612000-00011. View